Drug Trial Radar · NCT02793960
Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
Last checked: Nov 19, 2026Latest source record: Jun 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Aug 10, 2016
Primary completion
Aug 26, 2019
Study completion Aug 26, 2019
Sponsor
- Lead sponsor
- Shasa HuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BPGbio
- First posted
- Jun 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center study to investigate the effects of a topical cream on patients 12 years of age and older that have been diagnosed with epidermolysis bullosa.
Conditions
- Epidermolysis Bullosa
Interventions
topical BPM31510 3.0% CreamDrug
Application of drug to lesions of epidermolysis bullosa
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Miami Department of Dermatology
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.